Bio Chem Enz contd 8-1 Flashcards
This patient has a history of adrenocortical cancer and now presents with breast cancer based on the pathologic findings of her mass (the image shows high-grade invasive ductal carcinoma with prominent mitotic figures). In addition she has a strong family history (seen in her siblings and her father) of bone, breast, and blood cancers.
This family has Li-Fraumeni cancer syndrome, in which one copy of ?
the p53 tumor suppressor gene carries a mutation. This is an autosomal dominant disorder in which family members have a significantly increased risk of malignancy as children or young adults. Typical cancers include osteosarcomas, soft tissue sarcomas, early-onset breast cancers, adrenocortical tumors, and leukemias.
Mutations in APC would result in early-onset colon cancer. APC is located on chromosome 5 and is implicated in familial adenomatous polyposis coli (FAP), an autosomal dominant disorder. Patients with FAP develop hundreds of colon polyps as teenagers and young adults and are inevitably diagnosed with colon cancer by age 50. Mutations in APC can also cause Gardner syndrome, a subtype of FAP. Patients with this syndrome develop?
colorectal cancer as well as osseous and soft tissue tumors. They are also at increased risk of developing adrenal adenomas, but adrenal malignancy is rare. Gardner syndrome has not been linked to increased risk of the other malignancies seen in this family.
RET is the defective gene in multiple endocrine neoplasia type 2 (MEN2), which can be further categorized as either MEN2A or MEN2B. MEN syndromes are autosomal dominant. Patients with MEN2 syndrome are not at an increased risk of developing breast or ovarian cancer. Both MEN2A and MEN2B can manifest with?
pheochromocytoma and medullary thyroid carcinoma. Note that pheochromocytoma is a catecholamine-secreting neoplasm of the adrenal medulla, not the adrenal cortex. In addition, parathyroid tumors can also present with MEN2A, whereas marfanoid body habitus manifests with MEN2B.
BRCA1 and BRCA2 mutations are well documented familial breast cancer genes that are also associated with an increased risk of ?
early-onset ovarian malignancies. Neither gene has been shown to increase risk of other malignancies, such as the adrenal, bone, and blood cancers that patient and her family members have had.
Based on his clinical presentation of fatigue, shortness of breath, and jaundice after the administration of a new antibiotic, this patient appears to be experiencing an episode of intravascular hemolysis caused by a deficiency of glucose-6-phosphate dehydrogenase (G6PD). Patients with G6PD deficiency are more sensitive to oxidative drugs (eg, sulfa drugs, antimalarial agents) that result in the production of reactive oxygen species (ROS). Normally, when exposed to oxidative stress, red blood cells (RBCs) shunt glucose breakdown through the hexose monophosphate pathway, in which the enzyme G6PD produces reduced nicotinamide adenine dinucleotide phosphate (NADPH) from these products. NADPH allows for?
glutathione reductase to regenerate glutathione, which acts as a sink for ROS and protects hemoglobin and membranes from oxidative damage. However, when there is a G6PD deficiency, RBCs cannot produce enough reduced glutathione, resulting in oxidative damage of proteins and membranes.
Nicotinamide adenine dinucleotide (NAD+/NADH) is not involved in the hexose monophosphate (HMP) shunt. It is easily confused with NADP+/NADPH, which is involved in the HMP shunt.
Glucose-6-phosphate (G6P) is the first intermediate in the HMP shunt. Individuals with G6PD deficiency have a?
reduced ability to use this as a substrate in the HMP shunt, so G6P would be increased in this patient.
Phosphoribosyl pyrophosphate is a crucial precursor for purine nucleotides and may be decreased in patients with G6PD deficiency. However, it does not have clinically significant effects and would not be responsible for this patient’s presentation.
Reactive oxygen species, such as hydrogen peroxide, are produced by oxidizing agents such as sulfa drugs and would most likely be?
elevated, not underproduced, in this patient’s drug reaction.
This patient of African descent has severe pain in his back and legs and bony tenderness on exam, suggestive of vaso-occlusive crisis. His scleral icterus suggests ongoing hemolysis, and his family history of a father with similar symptoms who died of acute chest syndrome would suggest?
sickle cell disease.
Sickle cell anemia (HbSS) is a hemolytic disease of autosomal recessive inheritance caused by a point mutation in the hemoglobin β chain gene.Sickle cell hemoglobin, or hemoglobin S (HbS), is generated when glutamic acid at the sixth position of the β globin gene is replaced with valine. HbS occurs most frequently in populations previously exposed to Plasmodium falciparum malaria (ie, in Africa, India, and the Mediterranean).
Deficiency of the critical red blood cell enzyme glucose-6-phosphate dehydrogenase (G6PD) can lead to acute-onset hemolytic anemia and is typically seen in young men of African descent.
Decreased production of hemoglobin α chains is caused by α-thalassemia, which manifets as?
microcytic anemia. The disease’s effects vary depending on the extent of the defect and range from no symptoms to death.
Decreased production of hemoglobin β chains is caused by β- thalassemia, an inherited anemia typically found in patients of Mediterranean descent. Depending on the extent of the genetic abnormality, patients develop mild hypochromic microcytic anemia or a severe, transfusion-dependent anemia.
Deficiency of the erythrocyte cell membrane protein spectrin causes a ?
normocytic hemolytic anemia most common in patients of northern European descent. The condition, hereditary spherocytosis, would not cause the painful crises experienced by this patient and is uncommon in patients of African descent.
A 2-week-old infant is brought to his pediatrician for a well-baby check-up. His mother is concerned because he has not been feeding well and appears to have lost weight. This is confirmed on his growth chart; he has dropped from the 70th percentile for height and weight at birth to the 30th percentile in the past 2 weeks. His blood is found to contain excess amounts of leucine, isoleucine, and valine.
This infant is most likely to exhibit which of the following additional symptoms?
Maple syrup urine disease is associated with dystonia, which manifests as sustained muscle contractions resulting in twisting and repetitive movements or abnormal fixed postures. This usually manifests by 4 days of age but may not develop until the infant is 4–7 days old, depending on the amount of protein in the infant’s feeding regimen. Additionally, breastfeeding may delay onset into the second week. The mechanism for dystonia is thought to be due to altered levels of dopamine, GABA, and glutamate, and there are also associations with high serum leucine:tyrosine ratios.
Maple syrup urine disease (MSUD) can be associated with hypoglycemia, not hyperglycemia, a result of the body’s inability to metabolize the three nonaromatic, nonpolar amino acids (leucine, valine, isoleucine). Hypoglycemia in these patients is most pronounced during times of fasting. Though the mechanism of the hypoglycemia observed in these patients is not completely understood, it is speculated to be ?
secondary to preferential shunting of 3-carbon substrates from amino acids into glutamine. This shunting is thought to lead to decreased oxaloacetate production and subsequently impaired gluconeogenesis. The diagram illustrates the biochemistry of MSUD.
Red urine without visible RBCs is characteristic in rhabdomyolysis, which is a rapid breakdown of skeletal muscles. This condition is associated with excessive myoglobin in the urine, not elevation of three specific amino acids.
Renal stones are associated with?
alkaptonuria, not maple syrup urine disease.
Darkening of urine is classic for alkaptonuria, a disorder of tyrosine and phenylalanine metabolism.
Blood glucose is tightly regulated after a meal by an enzyme found in muscle tissues. This enzyme catalyzes one of the steps in the pathway to convert glucose to glycogen. In addition, this process is subject to feedback inhibition by glucose-6-phosphate.
Which of the following enzymes is being described?
Hexokinase is inhibited by glucose-6-phosphate and is found in all tissues in the body. Although present to some degree in liver and β-pancreatic cells, its function is negligible in these two tissues.
Glucokinase is found in the liver and in pancreatic β cells. It does not undergo feedback inhibition, allowing the liver to take up phosphorylate glucose at higher concentrations than peripheral tissues.
Phosphofructokinase-1 catalyzes the phosphorylation of ?
fructose-6-phosphate to fructose-1,6-bisphosphate in the glycolysis pathway.